Other · 5mg × 10 vials
this is a frog-derived peptide that acts on the exact same brain receptor as morphine, fentanyl, oxycodone, and heroin, except it is dramatically more potent per microgram and a microdose is a real dose.
Dermorphin is a 7-amino-acid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) originally isolated from the skin of the South American Phyllomedusa frog. It is a highly selective mu-opioid receptor (MOR) agonist with measured analgesic potency roughly 30 to 40 times that of morphine on a per-weight basis in animal models, and several hundred times morphine when delivered intrathecally. The selectivity for mu over delta and kappa receptors is what differentiates it pharmacologically from morphine and most synthetic opioids, but the downstream signaling cascade is the same one that drives the entire opioid class: G-protein coupled MOR activation leading to inhibition of adenylate cyclase, hyperpolarization of pain-relay neurons, and the well-known opioid effect profile (analgesia, euphoria, sedation, respiratory depression, constipation, tolerance, physical dependence). The D-alanine at position 2 is what makes dermorphin resist normal peptidase degradation and crosses the blood-brain barrier far more efficiently than most peptides, which is why microgram doses are systemically active.
In plain language: this is a frog-derived peptide that acts on the exact same brain receptor as morphine, fentanyl, oxycodone, and heroin, except it is dramatically more potent per microgram and a microdose is a real dose. There is nothing "natural" or "safer" about peptide opioids. The dependence, overdose, and respiratory depression profile is opioid-class.
Typical dose ranges by experience level — educational reference. Message us and we tailor it to you.
10 mcg is roughly equipotent to 300-400 mcg of morphine, which is itself a real opioid dose. Anyone who has never used opioids before should not be in this compound at all. If they are determined to proceed, the test-dose protocol is single dose, supervised, naloxone available, no other depressants in the system (no alcohol, no benzos, no sleep meds, no muscle relaxers, no other opioids, no GHB).
There is no clinical literature defining an intermediate human dose because dermorphin has never been through a human pain trial. These ranges are inferred from animal-to-human potency scaling and the small number of community self-reports. Anyone running it twice a week or more is on a path to physical dependence.
"Advanced" in this compound is not a flex. It is a flag. Users in this dose range are at meaningful overdose risk if they combine with any other CNS depressant, and at meaningful withdrawal risk if they have been dosing more than weekly. There is no safe advanced protocol for chronic use.
Straight talk — what people actually report, and what the studies measured.
Peer-reviewed studies and clinical guidelines — tap any to read the source.
original isolation and pharmacology
Read study ↗PubMedBroccardo M et al., Pharmacological data on dermorphins, Br J Pharmacol 1981analgesic potency and mu-opioid selectivity profile
Read study ↗PubMedNegri L et al., Dermorphin-related peptides from the skin of Phyllomedusa bicolor, Peptides 2000structure-activity, BBB penetration
Read study ↗PubMedMor A et al., Dermorphin: a 7-residue opioid peptide synthesized by Phyllomedusa, Biopolymers 1990biosynthesis and D-amino-acid significance
Read study ↗Physician commentaryAmerican Society of Addiction Medicine — National Practice Guideline for opioid use disorderopioid dependence and withdrawal framing
Read study ↗Physician commentaryCDC Clinical Practice Guideline for Prescribing Opioids for Pain, 2022opioid-class harm reduction and prescribing context
Read study ↗Aggregated sentiment from public forums & socials — real-world reports, not individual endorsements.
"Frog juice" / racetrack scandal: dermorphin was detected in dozens of US race horses 2011-2013 across multiple states; the Association of Racing Commissioners International classified it as a Class 1 prohibited substance after the New York Racing and Wagering Board and Louisiana State Racing Commission ran detection panels. This is the dominant historical…
Self-reported analgesia: users describe rapid onset (15-30 min SubQ) and a duration of analgesia in the 3-6 hour range
Self-reported euphoria: comparable to or exceeding morphine equivalent doses, which is the basis of the abuse-potential concern
Self-reported pruritis: very common in self-reports, often facial
Self-reported sedation: dose-dependent, more pronounced above 25 mcg
Self-reported withdrawal: opioid-class withdrawal syndrome reported by users who dosed daily for more than 2 weeks: rhinorrhea, GI upset, restless legs, insomnia, anxiety, sweating; duration 5-10 days for the acute phase
Route: SubQ (primary research route) or IV (research only)
Injection site: abdomen or outer thigh (research route), rotate sites
Storage: refrigerated, ~21-28 days. Discard if cloudy or off-color.
Notes: Microgram dosing is the entire safety story here. A 1 mg/ml concentration is too concentrated to dose safely with an insulin syringe (a single 1 IU graduation = 10 mcg, and overshooting by 1 IU doubles the dose). Always dilute to at least 200 mcg/ml so dosing graduations are readable, and use the smallest U-100 insulin syringe available (0.3 ml or 0.5 ml). Never reconstitute at 5 mg/ml. Have naloxone (Narcan) on hand before the first dose. Never administer alone.